Asked by: Sarah Owen (Labour - Luton North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to promote (a) culturally competent and (b) community-led prevention measures for older black men.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
This Government recognises the evidence that men of Black ethnicity are at a higher risk of some diseases. Tackling these inequalities is a top priority for the Government.
For example, black men are at higher risk of cardiovascular disease yet evidence shows that men in Black and Mixed ethnic groups are the least likely to receive lipid-lowering therapy or reach blood pressure targets. The National Health Service is tackling these inequalities through the Core20PLUS5 programme, a national approach to inform action to reduce healthcare inequalities in the most deprived areas. Hypertension and lipid management are one of the top clinical priorities for the framework, and the NHS is supporting systems where the burden of undiagnosed hypertension and untreated cholesterol is highest. Community based delivery models, such as pharmacy blood pressure checks and BP@Home, are also increasing access for underserved groups, including those in deprived and ethnically diverse communities.
Prostate cancer is another example where incidence rates are higher among Black men. We are jointly delivering the £42 million TRANSFORM trial with Prostate Cancer UK, with £16 million from the Department, which aims to find better ways of detecting prostate cancer and address inequalities, ensuring at least 10% of those invited to participate are Black men. In November, the first men began receiving letters from their general practitioners, inviting them to join the landmark trial designed to make diagnosis earlier, safer, and more effective.
There are around 17,000 people living with sickle cell disease in England. It is the fastest growing genetic condition in the country and is more common in people of Black African and Black Caribbean heritage (77% of patients) and in more deprived communities (47% of patients). NHS England, through the Sickle Cell and Thalassemia Quality Improvement programme, has stepped up a programme of work aligned to the Government’s 10-Year Health Plan particularly focusing on the shift to prevention, through a new education programme, that aims to develop a series of e-learning modules, training and communication material, which will focus on improving the knowledge and awareness about the condition, including for black men.
Asked by: Sarah Owen (Labour - Luton North)
Question to the Ministry of Housing, Communities and Local Government:
To ask the Secretary of State for Housing, Communities and Local Government, what process will be followed in determining the location of the headquarters for a new Strategic Mayoral Combined Authority that would include Luton.
Answered by Miatta Fahnbulleh - Parliamentary Under-Secretary (Housing, Communities and Local Government)
Any decision regarding the headquarters of a strategic authority would be the responsibility of that strategic authority, and not central Government.
Asked by: Sarah Owen (Labour - Luton North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the Government response to the Women and Equalities Committee report on Tackling HIV transmission, HC 1663, what the basis is for the estimate that Cabotegravir injectable PrEP will impact 2,000 people; whether that figure is a cap on availability; and what steps his Department will take to ensure equitable access to injectable PrEP.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Cabotegravir pre-exposure prophylaxis (PrEP) was recommended by the National Institute for Health and Care Excellence (NICE) as a clinically and cost-effective use for people who cannot have oral PrEP on 5 November 2025.
NICE estimated that up to 1,000 people would be eligible to receive cabotegravir injectable as PrEP but there is no cap on the number of people who may be eligible and therefore require and receive cabotegravir PrEP.
The new HIV Action Plan, published on 1 December 2025, sets out how the Government will enable every level of the healthcare system to work together to engage everyone in prevention, testing and treatment, tackling stigma, and reaching our ambition to end new HIV transmissions by 2030.
The Government will work with local authorities to expand alternative and digital delivery routes for injectable PrEP and audit current HIV technologies to identify gaps in provision. The UK Health Security Agency will publish local PrEP indicators to support action to reduce inequalities.